dturphoto/iStock via Getty Images
- A services agreement that Vaxart recently brokered with contract research organization hVIVO Services Ltd. "may be integral to its Covid vaccine candidate program," according to an SEC filing.
- That agreement, signed in late June, has hVIVO conducting a characterization study of the company's COVID-19 pill vaccine candidate. The purpose is to establish a dose of the Omicron challenge virus that will cause a safe and reliable infection in healthy volunteers.
- The trial is expected to have five cohorts and 36 participants.
- If the study is successful, Vaxart (NASDAQ:VXRT) will have hVIVO conduct a challenge study against the Omicron variant.
- Details also call for hVIVO to contract with a second client for another characterization study and a separate a separate challenge study.
- A deep dive into Vaxart (VXRT) was provided recently by Seeking Alpha contributor Bret Jensen.